Detalles de la búsqueda
1.
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Breast Cancer Res Treat
; 2024 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703285
2.
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.
Hum Mutat
; 20232023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38725546
3.
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.
Oncologist
; 27(7): e561-e570, 2022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35278078
4.
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
Breast Cancer Res
; 23(1): 86, 2021 08 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407845
5.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(1): e53-e65, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955138
6.
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Future Oncol
; 16(33): 2763-2778, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32781837
7.
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Invest New Drugs
; 37(1): 98-108, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29948356
8.
Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Pharmacogenet Genomics
; 28(11): 245-250, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334909
9.
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
Breast Cancer Res Treat
; 167(1): 249-256, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28913729
10.
11.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(3): e522, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33660385
12.
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
Breast Cancer Res Treat
; 156(3): 507-515, 2016 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27083178
13.
BRCA1 Alternative splicing landscape in breast tissue samples.
BMC Cancer
; 15: 219, 2015 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-25884417
14.
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Lancet Oncol
; 15(4): 406-14, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24636208
15.
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
BMC Cancer
; 14: 166, 2014 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-24606768
16.
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Breast
; 67: 94-101, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702070
17.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Res Sq
; 2023 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36824750
18.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Cancer Med
; 12(15): 16142-16162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37401034
19.
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Cancer
; 118(1): 241-7, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21717449
20.
Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
Breast Cancer Res Treat
; 165(2): 471, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28721639